Bioengineering Solutions for Manufacturing Challenges in CAR T Cells.

ABSTRACT: The next generation of therapeutic products to be approved for the clinic is anticipated to be cell therapies, termed "living drugs" for their capacity to dynamically and temporally respond to changes during their production ex vivo and after their administration in vivo. Genetically engineered chimeric antigen receptor (CAR) T cells have rapidly developed into powerful tools to harness the power of immune system manipulation against cancer. Regulatory agencies are beginning to approve CAR T cell therapies due to their striking efficacy in treating some hematological malignancies. However, the engineering and manufacturing of such cells remains a challenge for widespread adoption of this technology. Bioengineering approaches including biomaterials, synthetic biology, metabolic engineering,

SUBMITTER: Piscopo NJ 

PROVIDER: S-EPMC5796845 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature